Search Results
Your search for ,twO matches 12055 pages
Showing 2801 - 2850Evorpacept Alone and Combined With Pembrolizumab or Trastuzumab for Advanced Solid Tumors
In the phase I ASPEN-01 study reported in The Lancet Oncology, Nehal Lakhani, MD, and colleagues found evidence of activity of the CD47-blocking protein evorpacept in combination with pembrolizumab or trastuzumab for the treatment of advanced solid tumors. As stated by the investigators, “Both...
SITC 2021: New Data in Immunotherapy
The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. On this episode, we’ll hear from two researchers who presented data at the SITC meeting.
Newer Agents on the Horizon for Refractory or Relapsed DLBCL
Although treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains challenging, some newer therapies on the horizon offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy,...
FDA Expands Eligibility for COVID-19 Vaccine Boosters
On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...
Immunogenicity of COVID-19 Vaccination in Patients Receiving Systemic Therapy for Solid Tumors
In a Dutch study (VOICE) reported in The Lancet Oncology, Sjoukje F. Oosting, MD, and colleagues found that the mRNA-1273 (Moderna) COVID-19 vaccine produced adequate antibody responses in a majority of patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumors, with...
For Liver Metastases, Transarterial Radioembolization With Yttrium-90 Plus Chemotherapy May Delay Disease Progression
In the international phase III EPOCH trial, patients with colorectal liver metastases who experienced disease progression on first-line therapy derived significant benefit from treatment with transarterial yttrium Y-90 radioembolization in combination with systemic chemotherapy, according to Mary...
Study Reveals Genomic Differences Between 14 Tumor Types in Younger vs Older Adults
The results of a study published by Lee et al in Cell Reports suggest that several genetic hallmarks may play key roles in identifying precise treatment options for young adult patients with cancer. The investigators, who systematically compared the genomes of 14 different types of cancers that...
French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer
In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...
Numerous Regimens Proposed for Relapsed or Refractory Myeloma
Although patients with multiple myeloma can respond to initial treatment, once a patient has had three or four different types of therapy, and the disease is deemed relapsed or refractory, treatment becomes more complicated. This is related to both clinical characteristics, as patients may develop...
Use of Genomic Classifier Score May Help to Personalize Therapy for Men With High-Risk Prostate Cancer
A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...
Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer
In a single-institution prospective cohort study (CANVAX Cohort Study) reported in the Journal of Clinical Oncology, Naranbhai and colleagues assessed the immunogenicity of SARS–CoV-2 vaccines in patients with cancer. They found that immunogenicity varied among vaccines and that both antibody...
Novel Drug Combination May Help Children With Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy
A clinical trial recently published by Kutny et al in JAMA Oncology found that the combination of all-trans retinoic acid and arsenic trioxide was highly effective in children with standard- and high-risk acute promyelocytic leukemia (APL). Nearly all patients in the trial survived for 2 years...
NCI-Designated Cancer Center Compliance With CMS Price Transparency Rules
In a cross-sectional analysis reported in a research letter in JAMA Oncology, Chino et al found that a minority of National Cancer Institute (NCI)-designated cancer centers (NCI-CCs) were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency rules. Study ...
De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer
De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, a radiation oncologist at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, who was not involved in the RTOG 0815 study, commented: “The results of RTOG 0815 demonstrate that in the setting of contemporary dose-escalated...
No Survival Benefit but Improved Secondary Endpoints With Radiotherapy Plus Androgen Suppression in Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy have been shown to improve outcomes in intermediate-risk prostate cancer, but it is not clear whether giving both modalities upfront to newly diagnosed patients is of benefit. The phase III RTOG 0815 study presented ...
CheckMate 214: Longer Treatment-Free Survival With Immunotherapy vs Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
Patients with advanced renal cell carcinoma receiving first-line therapy with a checkpoint inhibitor combination of nivolumab plus ipilimumab experienced over twice as long treatment-free survival without toxicity compared with patients receiving the targeted therapy sunitinib, according to data...
International Conference Updates Guidelines for Advanced Breast Cancer
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least 5 years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC6), which was held virtually this year. The Advanced...
Showcasing 50 Years of Advances in Cancer Research and Treatment
The AACR Cancer Progress Report 2021, published on October 13, celebrates the gains made in cancer research since President Richard Nixon signed the National Cancer Act into law on December 23, 1971, especially against such life-threatening cancers as metastatic melanoma and lung cancer.1 The...
David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80
David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...
Expert Point of View: Monica Arnedos, MD, PhD
The invited discussant of BrighTNess,1 Monica Arnedos, MD, PhD, Head of the Breast Cancer Research Program at the Institut Bergonié in Bordeaux, France, said the findings add to growing support for using carboplatin in triple-negative breast cancer, but their clinical application could be...
BrighTNess: Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer
In patients with early resectable triple-negative breast cancer, not only did the addition of carboplatin to standard neoadjuvant chemotherapy improve pathologic complete response rates, it also improved 4-year event-free survival, regardless of BRCA status, according to the latest analysis of the...
Many Patients With Solid Tumors Mount an Adequate Response to SARS–CoV-2 Vaccine, Dutch Study Reports
Individuals with solid tumors had an appropriate, protective immune response to vaccination against SARS–CoV-2, at least with the mRNA-1273 vaccine, and side effects were no more common than in the general population, according to a large Dutch study.1 The study was reported during the European...
Susan G. Komen Announces $1.5 Million in Grants for Metastatic Breast Cancer Research
Susan G. Komen, the world’s leading breast cancer organization, recently announced the award of $1.5 million for three new research projects that examine unique areas focused on metastatic breast cancer. The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research...
ASTRO Honors 2021 Gold Medalists and Others
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2021 Gold Medal awards and other honors at the 63rd ASTRO Annual Meeting, held October 24 to 27 in Chicago. ASTRO Gold Medal Colleen A.F. Lawton, MD, FASTRO, and Lori J. Pierce, MD, FASTRO, FASCO, received the Gold ...
CDK4/6 Inhibitors Combined With Fulvestrant for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: FDA Analysis of Overall Survival
In an exploratory U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the addition of CDK4/6 inhibitor treatment to fulvestrant resulted in a consistent overall survival benefit vs placebo plus fulvestrant in...
Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers
People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...
Expert Point of View: Benjamin Besse, MD
Invited discussant Benjamin Besse, MD, of Gustave Roussy Cancer Center, Villejuif, France, was generally positive about the findings of Impower010 but said that longer-term follow-up of overall survival will be very important. “IMpower010 is the first adjuvant study establishing an immune...
IMpower010: Adjuvant Atezolizumab Improves Disease-Free Survival and NSCLC Relapse in Patients Whose Tumors Express PD-L1
Adjuvant immunotherapy with atezolizumab after standard chemotherapy improved disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of patients with stage II to IIIA non–small cell lung cancer (NSCLC), according to an...
International Medullary Thyroid Carcinoma Grading System: Detecting Adverse Outcomes
In a study reported in the Journal of Clinical Oncology, Xu et al developed a two-tiered international medullary thyroid carcinoma grading system that identifies high-grade disease associated with poorer outcomes. As stated by the investigators, “Currently, there is no widely accepted...
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable
Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...
Optimizing Adjuvant Therapy for Women With Estrogen Receptor–Positive, Node-Positive Breast Cancer
“Nodal status remains the single most important prognostic marker in outcomes for women with estrogen receptor–positive, HER2-negative breast cancer. For that reason, it makes sense to think about optimizing adjuvant therapy, including endocrine treatments, chemotherapy, and targeted therapy,”...
COVID-19 Sequelae Prevalence, Risk Factors, and Outcomes in Patients With Cancer
In a retrospective European study reported in The Lancet Oncology, David J. Pinato, PhD, and colleagues found that among patients with cancer who recovered from COVID-19 infection, a substantial proportion have sequelae that can affect survival and oncologic outcomes. Among patients on systemic...
Early Warning System Model May Help to Predict Deterioration of Hospitalized Patients With Cancer
About 9% of patients with cancer experience complications while hospitalized that lead to a deterioration in their condition, a transfer to the intensive care unit, or death. A multidisciplinary team of researchers at Washington University in St. Louis is developing a machine learning–based early...
Evidence for Efficacy of Sunitinib in Malignant Pheochromocytoma and Paraganglioma
Results from the phase II FIRSTMAPPP study support the potential use of the tyrosine kinase inhibitor sunitinib in two rare neuroendocrine malignancies—pheochromocytoma and paraganglioma. Sunitinib significantly improved the primary endpoint of progression-free survival vs placebo, according to...
Studies Find B7-H3 Protein May Be a Target for Prostate Cancer Treatment
The immune checkpoint protein B7-H3 may be a potential new target in treatment-resistant prostate cancers, according to two studies presented recently at the European Society for Medical Oncology (ESMO) Congress 2021. “Virtually every prostate cancer cell expresses some degree of B7-H3, which...
Addition of FDG-PET/CT and Staging Laparoscopy to the Initial Staging of Locally Advanced Gastric Cancer
In a Dutch cohort study (PLASTIC) reported in JAMA Surgery, Gertsen et al found that staging laparoscopy provided more diagnostic information resulting in change of treatment intent than F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) in patients with...
FDA Pipeline: Novel Treatments in Lymphoma, Nasopharyngeal Cancer, Solid Tumors, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for several kinds of lymphoma, as well as nasopharyngeal cancer; a Breakthrough Therapy designation for a treatment for patients with NTRK-positive advanced solid tumors; and Fast Track designation for...
Five-Year Follow-up of Olaparib Maintenance for Newly Diagnosed Patients With Advanced BRCA-Mutant Ovarian Cancer
As reported in The Lancet Oncology by Susana Banerjee, MBBS, PhD, and colleagues, 5-year follow-up of the pivotal phase III SOLO-1/GOG 3004 trial has shown a median progression-free survival of 56 months with maintenance olaparib following response to platinum-based chemotherapy in newly diagnosed...
Definitive Radiotherapy Without Systemic Therapy for Oligometastatic Renal Cell Carcinoma
In a single-center phase II study reported in The Lancet Oncology, Tang et al found that definitive radiotherapy in place of systemic therapy was feasible and effective for the treatment of oligometastatic renal cell carcinoma. As stated by the investigators, “The role of radiotherapy in metastatic ...
Modified FOLFIRINOX vs Cisplatin/Gemcitabine for Advanced Biliary Tract Cancer
In the phase II portion of a French phase II/III trial (PRODIGE 38 AMEBICA) reported in the Journal of Clinical Oncology, Phelip et al found that modified (m) FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) did not improve 6-month progression-free survival vs the combination of...
Overall Survival With Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer
As reported in JAMA Surgery by Huang et al, the Chinese phase III CLASS-01 trial has shown no difference in 5-year overall survival in patients with locally advanced gastric cancer who underwent laparoscopic vs open distal gastrectomy. The previously reported primary analysis of the trial showed no ...
FDA Approves Asciminib for Philadelphia Chromosome–Positive CML
On October 29, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the kinase inhibitor asciminib (Scemblix) for patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine...
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children Aged 5 Through 11 Years
On October 29, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children aged 5 through 11 years. The authorization was based on the FDA’s thorough and transparent evaluation of the data that...
Do Diet-Related Molecules Play a Role in the Development of Aggressive Prostate Cancer?
Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention. While...
Study Finds Incidence of Pancreatic Cancer May Be Rising in Younger Women
The incidence of pancreatic cancer—which historically has been higher in men than in women—has increased among both men and women during the past decade, with a significantly greater relative increase observed in women younger than age 55 years, and especially among those aged 15 to 34 years. These ...
Hepatic Arterial Infusion of FOLFOX vs Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Li et al found that hepatic arterial infusion chemotherapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin; FOLFOX-HAIC) improved overall survival vs transarterial chemoembolization (TACE) as first-line treatment for...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Study Finds Similar Survival Rates Among Patients With Metastatic Colorectal Cancer Younger and Older Than Age 50
Even though patients with metastatic colorectal cancer younger than age 50 tend to be more fit and receive more intensive treatment than older patients, survival for both groups is roughly the same, according to a study published by Lipsyc-Sharf et al in the Journal of the National Cancer...
David A. Palma, MD, PhD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs Surgery
David A. Palma, MD, PhD, of Ontario’s London Health Sciences Centre, discusses results of the ORATOR2 study, which compared two treatment options that could be de-escalated for patients with HPV-associated oropharyngeal squamous cell carcinoma: a lower-dose radiation approach (6 weeks instead of 7, ...
